GoodRx (GDRX) r&d spend was $121M in FY2025 (-2% YoY). The tables below show the complete quarterly and annual r&d spend history, sourced from SEC EDGAR 10-K and 10-Q filings.
Annual R&D Spend
Fiscal Year
R&D Spend
YoY
2025
$121M
-2%
2024
$124M
-9%
2023
$136M
-5%
2022
$143M
+14%
2021
$126M
+104%
2020
$62M
+111%
2019
$29M
-33%
2018
$44M
Recent Quarterly R&D Spend
Quarter
R&D Spend
Q2 2026
$27M
Q1 2026
$30M
Q4 2025
$29M
Q3 2025
$31M
Q2 2025
$30M
Q1 2025
$31M
Q4 2024
$32M
Q3 2024
$30M
Q2 2024
$31M
Q1 2024
$31M
Q4 2023
$32M
Q3 2023
$40M
Source: GDRX on EDGAR. Data from SEC EDGAR 10-K and 10-Q filings. Updated quarterly.